Last updated: May 29, 2026
Fosinopril Sodium Suppliers: Who Manufactures, Supplies APIs, and Where to Source Drug Product
Fosinopril sodium supply is primarily a function of (1) API producers for fosinopril sodium (or fosinopril intermediates converted through established salt formation steps) and (2) finished-dose manufacturers that hold approvals for branded or generic fosinopril sodium tablets under the FDA’s ANDA system. Market access depends on whether a given supplier can support tablet manufacturing, bioequivalence requirements, and regulatory documentation tied to specific strengths and label claims.
What companies supply fosinopril sodium active pharmaceutical ingredient (API)?
Fosinopril sodium API sourcing typically sits with established generic API manufacturers that also supply ACE-inhibitor intermediates and salt forms, often across multiple jurisdictions. In practice, procurement flows through:
- Contract API vendors that supply fosinopril API (or a defined salt form) with COA, DMF/ASMF documentation, and batch traceability.
- Integrated generic manufacturers that produce API in-house for their own ANDAs, then qualify external API fallback sources.
Because “fosinopril sodium suppliers” is strength- and route-dependent (tablet strengths, excipient systems, and polymorph/salt specifications), the actionable supplier shortlist must be tied to verifiable FDA/filing entities for the relevant ANDA(s) and strengths.
Which finished-dose manufacturers supply fosinopril sodium tablets in the US (ANDA holders)?
Finished-dose supply is governed by FDA approval status and whether the product is carried by:
- ANDA applicants and their contract manufacturers (CMOs)
- Branded holders (historically, where applicable)
- Market-specific distributors supplying retail/NDC channels
For US sourcing and regulatory alignment, “supplier” should be interpreted as the ANDA holder responsible for the commercial product and the contract manufacturer(s) listed in FDA submissions, not the raw-material vendor alone.
What is the FDA status of fosinopril sodium tablets (Orange Book) and how does it affect sourcing?
FDA market status determines whether a supplier can legally supply the strength in the US and which regulatory pathway applies. For sourcing decisions, the key linkage is:
- Orange Book listing of each fosinopril sodium tablet strength
- Corresponding patent and exclusivity flags (where listed) that influence authorized generic, label changes, and entry timing
If a strength is off-market or only carried by limited ANDA holders, inbound sourcing is constrained by those holders and their CMOs.
Which fosinopril sodium strengths are typically sold, and do suppliers differ by strength?
Supply varies by strength because ANDA manufacturing controls, tablet composition, and scale are strength-specific. Common practical implications for sourcing include:
- Different batch size and blending recipes by strength
- Different immediate-release excipient systems that require separate regulatory documentation
- Different packaging configurations and NDC ranges that change warehouse and distributor networks
As a result, a distributor might carry only selected strengths even when it sources across multiple strengths.
Are there biosimilar or biologic supply constraints for fosinopril sodium?
No. Fosinopril sodium is a small-molecule ACE inhibitor. Supply constraints are standard small-molecule CMC issues: API availability, polymorph/salt form control, impurity profiles, and tablet manufacturing capacity. No biologics-specific interchangeability or biosimilar exclusivity applies.
How do you identify reliable fosinopril sodium suppliers for procurement (API vs drug product)?
For procurement-grade supplier selection, the workflow should distinguish:
- API vendor qualification
- API COA, impurity profile, salt form specification
- ASMF/DMF alignment with the intended regulatory filing (if applicable)
- GMP audit history for API manufacturing and downstream traceability
- Finished-dose supplier qualification
- ANDA holder responsibility
- CMO manufacturing site qualification
- Batch release records mapped to NDC and strength
Procurement teams typically require document packages that mirror what FDA expects: CMC evidence, stability data, and validated analytical methods.
What patent and regulatory constraints can affect fosinopril sodium supply timing?
For generic small molecules, patent and exclusivity status can affect market entry and authorized generic dynamics. The practical effects are:
- If the Orange Book lists expiring patents for specific strengths, entry for some ANDAs may be delayed until those are cleared.
- If a generic has a Paragraph IV history or a settlement, that can shape “who supplies” for specific strengths at specific times.
This is a product-by-strength and filer-by-filer issue.
Do contract manufacturing (CMO) networks dominate fosinopril sodium supply?
Yes in most generic markets: API suppliers and CMO networks are often shared across multiple ACE inhibitors and other antihypertensives. The supplier that matters for stable supply is frequently the manufacturing site supporting the ANDA, not the brand of the distributor.
What generic entry risks exist for fosinopril sodium (supply interruption scenarios)?
Generic entry risk for fosinopril sodium generally manifests as:
- Limited number of ANDA holders for certain strengths leading to concentration risk
- API sourcing bottlenecks if API producers reduce capacity or change product focus
- CMC revalidation burdens if manufacturing sites change or if impurity controls require method updates
Those risks translate to procurement lead-time volatility and occasional NDC shortages.
How does fosinopril sodium supply compare with other ACE inhibitors (enalapril, lisinopril, ramipril)?
ACE inhibitors share similar procurement patterns:
- A narrower set of API manufacturers can dominate multiple molecules in the class
- Tablet supply is driven by ANDA manufacturing capacity and regional distribution agreements
- Salt-form and impurity-spec complexity differs by molecule, which can shift capacity availability during disruptions
From a sourcing standpoint, companies that diversify across ACE inhibitors often reduce exposure to a single bottleneck.
Key Takeaways
- Fosinopril sodium supply depends on distinguishing API suppliers from finished-dose ANDA holders and their CMO manufacturing sites.
- Orange Book status by strength governs US market access and the set of lawful suppliers for each NDC.
- Procurement risk is driven by ANDA holder concentration, CMO manufacturing capacity, and API availability for fosinopril sodium salt specifications.
FAQs
1) How do I find the correct fosinopril sodium ANDA holder for a specific NDC?
Use the FDA Orange Book listing for the exact strength and dosage form, then map the listed applicant/holder to the NDC.
2) Can an API supplier support multiple fosinopril sodium strengths from one manufacturing stream?
Often yes at the API level, but tablet strengths require strength-specific CMC controls, validation, and release testing under each finished-dose product.
3) What documents are typically required to qualify a fosinopril sodium API vendor?
COA, impurity profile/specification, GMP evidence, and regulatory file alignment (ASMF/DMF where applicable).
4) Are there common supply shortages for fosinopril sodium tablets?
Shortages can occur when ANDA holder production concentrates in limited CMOs or when API supply tightens, which can vary by strength.
5) Does fosinopril sodium have biologic interchangeability requirements?
No. It is a chemical small molecule; supply is governed by standard generic CMC and FDA product approval status.
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
